Published in Gastroenterology on March 02, 2011
Danazol Treatment for Telomere Diseases. N Engl J Med (2016) 3.39
Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis (2014) 2.24
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.49
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.33
Non-invasive assessment of liver fibrosis. Ann Gastroenterol (2012) 1.07
Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06
Transient elastography: Kill two birds with one stone? World J Hepatol (2013) 1.03
Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One (2014) 1.02
Noninvasive diagnosis of liver fibrosis: The importance of being reimbursed. Can J Gastroenterol Hepatol (2015) 0.97
Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol (2013) 0.96
Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) (2011) 0.95
The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations. Can J Gastroenterol Hepatol (2014) 0.94
Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 2, Diagnostic Performance, Confounders, and Future Directions. AJR Am J Roentgenol (2015) 0.92
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis. J Gastroenterol (2014) 0.91
Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU. Crit Care (2011) 0.90
Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS One (2014) 0.90
Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf) (2013) 0.90
Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther (2012) 0.89
Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond. World J Gastroenterol (2014) 0.89
Liver elastography, comments on EFSUMB elastography guidelines 2013. World J Gastroenterol (2013) 0.89
Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol (2014) 0.87
The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease. Med Devices (Auckl) (2014) 0.87
Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol (2014) 0.85
Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol (2013) 0.85
Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol (2016) 0.85
Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 0.84
Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression. Aliment Pharmacol Ther (2014) 0.84
Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol (2015) 0.83
Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One (2015) 0.81
Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis. Medicine (Baltimore) (2016) 0.80
Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. Mediators Inflamm (2015) 0.80
Noninvasive methods for the assessment of liver fibrosis: a window open on the future? Hepatology (2011) 0.80
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Can J Gastroenterol Hepatol (2016) 0.78
Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. Int J Hepatol (2015) 0.78
Non-invasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol (2014) 0.78
Liver ultrasound elastography: More than staging the disease. World J Hepatol (2015) 0.78
Real-time two-dimensional shear wave ultrasound elastography of the liver is a reliable predictor of clinical outcomes and the presence of esophageal varices in patients with compensated liver cirrhosis. Croat Med J (2015) 0.77
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. PLoS One (2015) 0.77
Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol (2015) 0.77
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons. Clin Infect Dis (2015) 0.77
Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C. J Gastroenterol (2013) 0.77
Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. J Gastroenterol Hepatol (2016) 0.77
The Application of Liver Stiffness Measurement in Residents Without Overt Liver Diseases Through a Community-Based Screening Program. Medicine (Baltimore) (2016) 0.77
IP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection. PLoS One (2012) 0.77
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol (2016) 0.76
Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort. PLoS One (2015) 0.76
Prediction of fibrosis in hepatitis C patients: assessment using hydroxyproline and oxidative stress biomarkers. Virusdisease (2013) 0.76
Biomarkers in liver disease: emerging methods and potential applications. Int J Hepatol (2012) 0.75
Use of Wireless Capsule Endoscopy for the Diagnosis and Grading of Esophageal Varices in Patients With Portal Hypertension: A Systematic Review and Meta-Analysis. J Clin Gastroenterol (2016) 0.75
Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol. BMC Infect Dis (2015) 0.75
Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C. Open Forum Infect Dis (2016) 0.75
Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India. Open Forum Infect Dis (2016) 0.75
Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS One (2016) 0.75
Incidence and Predictors of Advanced Liver Fibrosis by a Validated Serum Biomarker in Liver Transplant Recipients. Can J Gastroenterol Hepatol (2017) 0.75
Does pressure cause liver cirrhosis? The sinusoidal pressure hypothesis. World J Gastroenterol (2016) 0.75
Chronic permanent hypoxemia predisposes to mild elevation of liver stiffness. World J Gastroenterol (2014) 0.75
Comparison of three dimensional strain volume reconstructions using SOUPR and wobbler based acquisitions: A phantom study. Med Phys (2016) 0.75
Role of spleen elastography in patients with chronic liver diseases. World J Gastroenterol (2016) 0.75
New combined parameter of liver and splenic stiffness as determined by elastography in healthy volunteers. Saudi J Gastroenterol (2016) 0.75
Imaging Based Methods of Liver Fibrosis Assessment in Viral Hepatitis: A Practical Approach. Interdiscip Perspect Infect Dis (2015) 0.75
Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years. PLoS One (2016) 0.75
Performance of transient elastography and serum fibrosis biomarkers for non-invasive evaluation of recurrent fibrosis after liver transplantation: A meta-analysis. PLoS One (2017) 0.75
Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS One (2017) 0.75
Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions. Radiographics (2016) 0.75
Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf) (2017) 0.75
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology (2010) 3.22
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology (2010) 2.58
Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol (2006) 2.37
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology (2006) 2.07
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol (2010) 2.02
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology (2012) 1.94
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol (2011) 1.79
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int (2012) 1.71
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol (2010) 1.70
Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology (2013) 1.64
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int (2008) 1.62
Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis (2003) 1.59
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut (2010) 1.55
Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology (2009) 1.55
An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. Eur J Radiol (2012) 1.51
Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS (2002) 1.50
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal. Clin Transplant (2002) 1.48
Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr (2007) 1.47
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry (2005) 1.41
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology (2006) 1.34
Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol (2011) 1.32
Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl (2005) 1.28
Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol (2012) 1.26
Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg (2005) 1.18
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol (2009) 1.18
Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int (2010) 1.16
Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology (2013) 1.07
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol (2012) 1.05
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med (2013) 1.02
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol (2009) 1.02
Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection. J Infect Dis (2004) 0.99
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int (2009) 0.97
Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl (2006) 0.96
Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology (2014) 0.95
Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol (2002) 0.95
Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol (2008) 0.94
Relationship between the severity of hepatitis C virus-related liver disease and the presence of Helicobacter species in the liver: a prospective study. World J Gastroenterol (2006) 0.93
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One (2012) 0.92
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology (2011) 0.92
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int (2014) 0.90
Effects of Helicobacter pylori infection on gut appetite peptide (leptin, ghrelin) expression in elderly inpatients. J Gerontol A Biol Sci Med Sci (2006) 0.89
Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol (2006) 0.89
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol (2009) 0.89
Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol (2010) 0.88
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology (2006) 0.88
Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping styles. Psychosomatics (2005) 0.88
Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999-2004. Gastroenterol Clin Biol (2007) 0.87
Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy. Antivir Ther (2013) 0.86
Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol (2005) 0.86
Remission of protein-losing enteropathy after nodal lymphoma treatment in a patient with primary intestinal lymphangiectasia. Eur J Gastroenterol Hepatol (2005) 0.84
Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther (2009) 0.83